Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;139:237-242.
doi: 10.1016/j.visres.2017.05.010. Epub 2017 Aug 8.

Erythropoietin in Diabetic Retinopathy


Erythropoietin in Diabetic Retinopathy

Gerard Reid et al. Vision Res. .


Over the past years, knowledge has expanded with regards to the multiple roles played by erythropoietin (EPO) in the body. Once believed to be a hormone synthesised in the kidney and involved only in the modulation of erythrocyte production, it is recognised now that EPO can be produced in many tissues, including the retina, and by many cells. In these tissues EPO is released in response to "tissue injury" and appears to have protective functions. Despite the extensive research conducted to date, the cues leading to release of EPO and its effects in the normal and diseased retina have not been fully elucidated. In vitro and in vivo experimental studies as well as small interventional clinical studies suggest a potential beneficial effect of externally administered EPO in early diabetic retinopathy and diabetic macular oedema. In contrast, controversy exists with regards to the possible use of EPO in proliferative diabetic retinopathy. Non-erythropoietic EPO-derived peptides, produced with the aim of increasing effectiveness and reducing side effects of EPO, are currently under investigation in early phase clinical trials.

Keywords: ARA290; Diabetic macular edema; Diabetic retinopathy; Erythropoietin; Erythropoietin receptor; Proliferative diabetic retinopathy; β common receptor.

Similar articles

See all similar articles

Cited by 2 articles

MeSH terms